A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT ID: NCT05633355
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
187 participants
INTERVENTIONAL
2023-01-30
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05704738
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT06224192
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
NCT05651711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rocatinlimab
Rocatinlimab will be administered subcutaneously every 4 weeks (Q4W) for 52 weeks with one additional dose at Week 2.
Rocatinlimab
Subcutaneous (SC) injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rocatinlimab
Subcutaneous (SC) injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has a diagnosis of AD (according to American Academy of Dermatology Consensus Criteria \[Eichenfield, 2014\]) that has been present for at least 12 months before signing of informed consent
* Prior to informed consent, history of inadequate response to topical corticosteroids (TCS) of medium to higher potency (with or without topical calcineurin inhibitors \[TCI\] as appropriate) or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks)
* Eczema Area and Severity Index (EASI) score ≥ 12
* vIGA-AD score ≥ 3
* ≥ 10% BSA of AD involvement at day 1 pre-enrollment
Exclusion Criteria
* Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
* Systemic corticosteroids
* Systemic immunosuppressants
* Phototherapy
* Oral or topical janus kinase inhibitors
* Treatment with any of the following agents within 1 week before day 1 pre-enrollment:
* Topical PDE4 inhibitors
* Other topical immunosuppressive agents (not including TCS/TCI)
* Combination topical agents containing a high- or super-high potency corticosteroid
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Childrens Hosptial
Phoenix, Arizona, United States
Medical Advancement Centers of Arizona
Tempe, Arizona, United States
Dermatology Trial Associates
Bryant, Arkansas, United States
Little Rock Allergy and Asthma Clinical Research Center
Little Rock, Arkansas, United States
University of California Irvine
Irvine, California, United States
University of California Los Angeles
Los Angeles, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Manlio Dermatology
Kissimmee, Florida, United States
Palm Springs Community Health Center
Miami, Florida, United States
ARA Professionals Limited Liability Corporation
Miami, Florida, United States
Deluxe Health Care LLC
Miami Lakes, Florida, United States
Bluegrass Allergy Care
Lexington, Kentucky, United States
Windsor Dermatology dba Eczema Treatment Center of New Jersey
East Windsor, New Jersey, United States
Smart Medical Research Inc
Jackson Heights, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Auni Allergy
Findlay, Ohio, United States
Oregon Medical Research Center
Portland, Oregon, United States
DermDox Dermatology, LLC
Sugarloaf, Pennsylvania, United States
Driscoll Childrens Hospital
Corpus Christi, Texas, United States
Modern Research Associates
Dallas, Texas, United States
Center for Clinical Studies
Houston, Texas, United States
University of Utah MidValley Dermatology
Murray, Utah, United States
Cinme - Centro de Investigaciones Metabolicas
CABA, Buenos Aires, Argentina
Fundacion Cidea
Buenos Aires, Distrito Federal, Argentina
Instituto de Neumonologia y Dermatologia
Buenos Aires, Distrito Federal, Argentina
Centro de Investigaciones Clinicas Instituto Especialidades De La Salud De Rosario
Rosario, Santa Fe Province, Argentina
Fundacion Estudios Clinicos
Rosario, Santa Fe Province, Argentina
Instituto de Diagnostico ABC
Rosario, Santa Fe Province, Argentina
Woden Dermatology
Phillip, Australian Capital Territory, Australia
The Skin Hospital
Darlinghurst, New South Wales, Australia
Premier Specialists
Kogarah, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
The Skin Centre
Benowa, Queensland, Australia
Veracity Clinical Research
Woolloongabba, Queensland, Australia
Monash Childrens Hospital
Clayton, Victoria, Australia
Institute for Skin Health and Immunity
Mitcham, Victoria, Australia
Universidade Federal do Parana
Curitiba, Paraná, Brazil
Hospital Ernesto Dornelles
Porto Alegre, Rio Grande do Sul, Brazil
Fundacao Abc - Centro Univ Fmabc
Santo André, São Paulo, Brazil
Ispem-Instituto São José dos Campos em Pesquisas Médicas
São José dos Campos, São Paulo, Brazil
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
São Paulo, São Paulo, Brazil
Alergoalfa Nucleo Diagnostico Tratamento e Pesquisa Clinica em Alergia
São Paulo, , Brazil
Dermatology Research Institute Incorporated
Calgary, Alberta, Canada
Stratica Dermatology
Edmonton, Alberta, Canada
Vida Clinical Research
Edmonton, Alberta, Canada
Winnipeg Clinic Dermatology Research
Winnipeg, Manitoba, Canada
Skincare Studio
St. John's, Newfoundland and Labrador, Canada
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, Canada
Halton Pediatric Allergy
Burlington, Ontario, Canada
LEADER Research
Hamilton, Ontario, Canada
Triple A Lab
Hamilton, Ontario, Canada
JRB Research Incorporated
Ottawa, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
Toronto Research Centre Inc
Toronto, Ontario, Canada
FACET Dermatology
Toronto, Ontario, Canada
University of Hong Kong, Queen Mary Hospital
Hong Kong, , Hong Kong
Korea University Ansan Hospital
Ansansi, Gyeonggido, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
National Medical Center
Seoul, , South Korea
Kyung Hee University Hospital at Gangdong
Seoul, , South Korea
The Catholic University of Korea Seoul St Marys Hospital
Seoul, , South Korea
Chung-Ang University Hospital
Seoul, , South Korea
Hallym University Kangnam Sacred Heart Hospital
Seoul, , South Korea
Ewha Womans University Seoul Hospital
Seoul, , South Korea
Bezmialem Vakif Universitesi Hastanesi
Istanbul, , Turkey (Türkiye)
Istanbul Universitesi Cerrahpasa Tip Fakultesi
Istanbul, , Turkey (Türkiye)
Bakircay Universitesi Cigli Egitim ve Arastirma Hastanesi
Izmir, , Turkey (Türkiye)
Erciyes Universitesi Tip Fakultesi Hastanesi
Kayseri, , Turkey (Türkiye)
Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi
Samsun, , Turkey (Türkiye)
Bristol Royal Hospital for Children
Bristol, , United Kingdom
Velocity Clinical Research, High Wycombe
High Wycombe, , United Kingdom
Alder Hey Childrens Hospital
Liverpool, , United Kingdom
Whipps Cross University Hospital
London, , United Kingdom
St Thomas Hospital
London, , United Kingdom
Carn to Coast Health Centres
Redruth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Guttman-Yassky E, Simpson E, Bissonnette R, Eichenfield LF, Kabashima K, Luna PC, Hercogova JT, Spelman L, Worm M, Esfandiari E, Arai T, Mano H, Charuworn P, Wang A, Kricorian G. ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis. Immunotherapy. 2025 Feb;17(2):83-94. doi: 10.1080/1750743X.2025.2464528. Epub 2025 Feb 26.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-001548-99
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
20210263
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.